Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
Diabetes Technol Ther. 2009 Oct;11(10):641-7. doi: 10.1089/dia.2009.0035.
Interference studies of four glucose meters (Nova Biomedical [Waltham, MA] StatStrip [hospital grade], Roche Diagnostics [Indianapolis, IN] Accu-Chek Aviva [home grade], Abbott Diabetes Care [Alameda, CA] Precision FreeStyle Freedom [home grade], and LifeScan [Milpitas, CA] SureStep Flexx [hospital grade]) were evaluated and compared to the clinical laboratory plasma hexokinase reference method (Roche Hitachi 912 chemistry analyzer). These meters were chosen to reflect the continuum of care from hospital to home grade meters commonly seen in North America.
Within-run precision was determined using a freshly prepared whole blood sample spiked with concentrated glucose to give three glucose concentrations. Day-to-day precision was evaluated using aqueous control materials supplied by each vendor. Common interferences, including hematocrit, maltose, and ascorbate, were tested alone and in combination with one another on each of the four glucose testing devices at three blood glucose concentrations.
Within-run precision for all glucose meters was <5% except for the FreeStyle (up to 7.6%). Between-day precision was <6% for all glucose meters. Ascorbate caused differences (percentage change from a sample without added interfering substances) of >5% with pyrroloquinolinequinone (PQQ)-glucose dehydrogenase-based technologies (Aviva and Freestyle) and the glucose oxidase-based Flexx meter. Maltose strongly affected the PQQ-glucose dehydrogenase-based meter systems. When combinations of interferences (ascorbate, maltose, and hematocrit mixtures) were tested, the extent of the interference was up to 193% (Aviva), 179% (FreeStyle), 25.1% (Flexx), and 5.9% (StatStrip). The interference was most pronounced at low glucose (3.9-4.4 mmol/L).
All evaluated glucose meter systems demonstrated varying degrees of interference by hematocrit, ascorbate, and maltose mixtures. PQQ-glucose dehydrogenase-based technologies showed greater susceptibility than glucose oxidase-based systems. However, the modified glucose oxidase-based amperometric method (Nova StatStrip) was less affected in comparison with the glucose oxidase-based photometric method (LifeScan SureStep Flexx).
对四种血糖仪(美国万泰的 Nova Biomedical [Waltham,MA] StatStrip [医院级]、印第安纳波利斯的罗氏诊断 Roche Diagnostics [Indianapolis,IN] Accu-Chek Aviva [家用级]、加利福尼亚州阿拉米达的雅培糖尿病护理 Abbott Diabetes Care [Alameda,CA] Precision FreeStyle Freedom [家用级]和加利福尼亚州米尔皮塔斯的 LifeScan [Milpitas,CA] SureStep Flexx [医院级])进行了干扰研究,并将其与临床实验室血浆己糖激酶参考方法(罗氏日立 912 化学分析仪)进行了比较。这些血糖仪的选择反映了北美从医院到家用级血糖仪的连续护理。
使用新制备的全血样本,用浓缩葡萄糖进行干扰,以获得三种葡萄糖浓度,来确定批内精密度。使用每个供应商提供的水基对照材料评估日间精密度。在三个血糖浓度下,对四种葡萄糖检测设备中的每一种,单独和组合测试了常见干扰物(包括血细胞比容、麦芽糖和抗坏血酸)。
除了 FreeStyle(高达 7.6%)外,所有血糖仪的批内精密度均<5%。所有血糖仪的日间精密度均<6%。抗坏血酸导致基于吡咯喹啉醌(PQQ)-葡萄糖脱氢酶的技术(Aviva 和 FreeStyle)和基于葡萄糖氧化酶的 Flexx 血糖仪的差异(与未添加干扰物质的样本相比的百分比变化)>5%。麦芽糖强烈影响基于 PQQ-葡萄糖脱氢酶的计系统。当测试干扰物(抗坏血酸、麦芽糖和血细胞比容混合物)的组合时,干扰的程度高达 193%(Aviva)、179%(FreeStyle)、25.1%(Flexx)和 5.9%(StatStrip)。在低血糖(3.9-4.4mmol/L)时,干扰最为明显。
所有评估的血糖仪系统均显示出血细胞比容、抗坏血酸和麦芽糖混合物的不同程度的干扰。基于 PQQ-葡萄糖脱氢酶的技术比基于葡萄糖氧化酶的系统更容易受到干扰。然而,与基于葡萄糖氧化酶的比色法(LifeScan SureStep Flexx)相比,改良的基于葡萄糖氧化酶的安培法(Nova StatStrip)受影响较小。